

726,000 Results

Any time ▾

Challenges and Opportunities for Pancreatic Cancer ...

<https://pubmed.ncbi.nlm.nih.gov/32946773>

Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types. ...
Challenges and Opportunities for Pancreatic Cancer Immunotherapy Cancer Cell. 2020 Dec...

Cited by: 9

Author: Adham S. Bear, Robert H. Vonderheide, ...

Publish Year: 2020

Pancreatic cancer: challenges and opportunities | BMC ...

<https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-018-1215-3> ▾

Nov 22, 2018 · We briefly introduce the most groundbreaking advances in pancreatic cancer diagnosis and clinical treatment strategies over the past 15 years, including surgery, chemotherapy, endoscopy...

Cited by: 23

Author: Huiyun Zhu, Tuo Li, Yiqi Du, Min Li

Publish Year: 2018

PEOPLE ALSO ASK

Is pancreatic cancer increasing? ▾

What is the survival rate for pancreatic cancer? ▾

What is the tumour microenvironment in pancreatic cancer? ▾

How is pancreatic cancer different from other cancers? ▾

[Feedback](#)

New Strategies in Pancreatic Cancer: Emerging ...

<https://clincancerres.aacrjournals.org/content/16/17/4313> ▾

Sep 01, 2010 · Background. Pancreatic cancer (PC) is the fourth leading cause of cancer-related death for both men and women in the United States. It is one of the most lethal malignancies, with a 5-year...

Cited by: 73

Author: Donghui Li, James L. Abbruzzese

Publish Year: 2010

Challenges and Opportunities for Pancreatic Cancer ...

[https://cancer-cell.com/cancer-cell/fulltext/S1455-5400\(20\)30445-2](https://cancer-cell.com/cancer-cell/fulltext/S1455-5400(20)30445-2)



ALL

IMAGES

VIDEOS

196,000 Results

Current and Emerging Therapies in Metastatic Pancreatic Cancer

<https://clincancerres.aacrjournals.org/content/23/7/1670> ▼

Apr 01, 2017 · Gemcitabine. Studies aiming to improve **pancreatic cancer therapy** are almost always conducted in the metastatic setting. From a historical perspective, gemcitabine was the first agent approved by the FDA for the treatment of **pancreatic cancer** and was approved based on an improvement in clinical benefit.

Cited by: 85

Author: Gulam Abbas Manji, Kenneth P. Olive, Yvon...

Publish Year: 2017

Estimated Reading Time: 10 mins

Pancreatic cancer: challenges and opportunities | BMC ...

<https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1215-3> ▼

Nov 22, 2018 · **Pancreatic cancer** is the fourth leading cause of **cancer**-related death in the United States, with increasing incidence. The mortality rate of **pancreatic cancer** is rising rapidly, and is projected to be the second most common of all malignant tumors by 2030. However, the diagnosis and **therapy** of **pancreatic cancer** remain a formidable challenge.

Cited by: 39

Author: Huiyun Zhu, Tuo Li, Yiqi Du, Min Li

Publish Year: 2018

Estimated Reading Time: 8 mins

PEOPLE ALSO ASK

What are the advances in pancreatic cancer treatment? ▼

Are there any clinical trials for pancreatic cancer? ▼

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 63469

Manuscript Type: MINIREVIEWS

Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities

Current and emerging therapeutic strategies in pancreatic cancer

Abstract

Pancreatic carcinoma is one of the leading causes of cancer-related deaths worldwide. Despite early detection and advances in therapeutics, the prognosis remains dismal. The outcome and therapeutic approach are dependent on the stage of pancreatic carcinoma at the time of diagnosis. The standard of care is surgery followed by adjuvant chemotherapy. The advent of newer drugs has changed the landscape of adjuvant therapy. Moreover, recent trials have highlighted the role of neoadjuvant

Match Overview

1	Internet 117 words crawled on 03-Sep-2020 journals.sagepub.com	2%
2	Internet 76 words crawled on 21-Sep-2020 synapse.koreamed.org	1%
3	Internet 35 words crawled on 10-Oct-2020 11000researchdata.s3.amazonaws.com	1%
4	Internet 27 words crawled on 26-Jul-2021 www.ClinicalTrials.gov	<1%
5	Crossref 19 words Gregory M. Heerstand, James D. Murphy, Andrew M. Lowy ... Approach to Patients With Pancreatic Cancer Without Dete	<1%
6	Crossref 18 words Roberto Coppola, L. William Traverso, John P. Hoffman, C ... arles M. Volmer: "Pancreas Cancer 2008". Pancreatology.	<1%
7	Internet 15 words crawled on 24-Dec-2020 test.dovepress.com	<1%
8	Crossref 14 words Lorenza Landi, Federico Cappuzzo: "How selecting best up front therapy for metastatic disease?—Focus on ROS1-r ...	<1%

国内版

国际版

Current and emerging therapeutic strategies in pancreatic cancer: (



ALL

IMAGES

VIDEOS

198,000 Results

Any time ▾

Therapeutic developments in pancreatic cancer: current and ...

<https://www.nature.com/articles/s41575-018-0005-x>

May 01, 2018 · **Challenges** include identification of at-risk populations for screening and prevention, early detection by advanced imaging and novel **cancer** (bio)markers and most notably better **therapeutic options...**

Cited by: 344

Author: John P. Neoptolemos, Jörg Kleeff, Jörg Kl...

Publish Year: 2018

Current and Emerging Therapies in Metastatic Pancreatic ...

<https://clincancerres.aacrjournals.org/content/23/7/1670> ▾

Apr 01, 2017 · Gemcitabine. Studies aiming to improve **pancreatic cancer therapy** are almost always conducted in the metastatic setting. From a historical perspective, gemcitabine was the first agent approved by the FDA for the treatment of **pancreatic cancer** and was approved based on an improvement in clinical benefit.

Cited by: 85

Author: Gulam Abbas Manji, Kenneth P. Olive, Yv...

Publish Year: 2017

Estimated Reading Time: 10 mins

PEOPLE ALSO ASK

What are the advances in pancreatic cancer treatment? ▾

Are there any clinical trials for pancreatic cancer? ▾

How is the tumor microenvironment of pancreatic cancer unique? ▾

Why are immune cells downregulated in pancreatic cancer? ▾

Feedback

Pancreatic cancer: challenges and opportunities | BMC ...

<https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1215-3> ▾

Nov 22, 2018 · **Pancreatic cancer** is the fourth leading cause of cancer-related death in the United States, with increasing incidence. The mortality rate of **pancreatic cancer** is rising rapidly, and is projected to be the second most common of all malignant tumors by 2030. However, the diagnosis and